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Abstract
Introduction: We present two consensus definitions of advanced and late stage liver disease being used as
epidemiological tools. These definitions can be applied to assess the morbidity caused by liver diseases in different
health care systems. We focus is on hepatitis B and C virus infections, because effective and well tolerated
treatments for both of these infections have greatly improved our ability to successfully treat and prevent advanced
and late stage disease, especially if diagnosed early. A consensus definition of late presentation with viral hepatitis is
important to create a homogenous, easy-to-use reference for public health authorities in Europe and elsewhere to
better assess the clinical situation on a population basis.
Methods: A working group including viral hepatitis experts from the European Association for the Study of the
Liver, experts from the HIV in Europe Initiative, and relevant stakeholders including patient advocacy groups, health
policy-makers, international health organisations and surveillance experts, met in 2014 and 2015 to develop a draft
consensus definition of late presentation with viral hepatitis for medical care. This was refined through subsequent
consultations among the group.
Results: Two definitions were agreed upon. Presentation with advanced liver disease caused by chronic viral
hepatitis for medical care is defined as a patient with chronic hepatitis B and C and significant fibrosis (≥ F3 assessed
by either APRI score > 1.5, FIB-4 > 3.25, Fibrotest > 0.59 or alternatively transient elastography (FibroScan) > 9.5 kPa or
liver biopsy ≥METAVIR stage F3) with no previous antiviral treatment. Late stage liver disease caused by chronic
viral hepatitis is clinically defined by the presence of decompensated cirrhosis (at least one symptom of the
following: jaundice, hepatic encephalopathy, clinically detectable ascites, variceal bleeding) and/or hepatocellular
carcinoma.
Conclusion: These consensus definitions will help to improve epidemiological understanding of viral hepatitis
and possibly other liver diseases, as well as testing policies and strategies.
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Introduction
Over 13 million adults are living with hepatitis B, and 15
million with hepatitis C, in the World Health Organization
(WHO) European Region [1–4]. The prevalence of chronic
hepatitis B virus (HBV) infection (commonly defined as
the persistence of hepatitis B surface antigen for six
months or more) and chronic hepatitis C virus (HCV)
infection (as determined by the persistence of hepatitis C
nucleic acid or HCV core antigen for more than six or 121
months) ranges from 0.1% to 6% across Europe, with major
differences between countries and population subgroups
[2–4]. Chronic HBV and HCV infections may remain clin-
ically silent for decades, and symptoms do occur at a late
stage. Diagnosis in the absence of widespread screening
programmes may therefore be based on signs of late stage
liver disease such as hepatic decompensation, variceal
bleeding or hepatocellular carcinoma.
Many people with chronic HBV and/or HCV infection
are go undiagnosed [5]. Of those already diagnosed,
many are not necessarily linked to parts of the health-
care system that are able to provide comprehensive care
(e.g. to accurately classify the extent of liver disease and
provide treatment when indicated) [6]. Consequently, a
large (but undetermined) proportion of the chronically
infected population enters comprehensive care only after
developing liver disease-related clinical symptoms.
Effective and well tolerated treatments for both HBV
and HCV infection have greatly improved our ability treat
patients successfully, especially if they are diagnosed early
[7–10]. In asymptomatic individuals, treatment is indi-
cated for those at increased risk of symptomatic chronic
liver disease, and those at risk of transmitting the infec-
tion. All patients with symptomatic disease should be
treated. For many, treatment can prevent further progres-
sion of liver disease to liver cirrhosis, and can even revert
existing liver fibrosis [7, 8].
In most European countries, it remains unknown as to
what extent testing policies and strategies succeed in
identifying the undiagnosed population during the
course of their disease. The extent to which diagnosed
patients are linked to and retained in sections of the
healthcare system that are able to provide comprehen-
sive care is also unknown.
To fully exploit the strategic use of treatment and to
optimise its benefit, infected persons in need of treat-
ment must enter comprehensive care before their liver
disease progresses to considerable liver damage. Patients
with advanced liver fibrosis may be considered as “late
presenters”. Of these, a subgroup of individuals with
“late stage liver disease”, such as decompensated liver
cirrhosis, portal hypertension or hepatocellular carcin-
oma, can be further defined as a subgroup where there
is indisputable evidence that earlier initiation of treat-
ment would have provided significant benefit. These
definitions will help quantify the proportion of cases
missing timely diagnosis and treatment.
Method/process of developing a consensus
definition of late presentation with viral hepatitis
In 2014, a group of viral hepatitis experts within the
European Association for the Study of the Liver (EASL)
and the HIV in Europe Initiative [11] formed a working
group to develop a consensus definition of late presenta-
tion with viral hepatitis. Key stakeholders were invited
to participate, including patient advocacy groups,
health policy-makers, international health organisations,
surveillance experts and medical experts. The consensus-
building process involved all of the important constituen-
cies in Europe involved in both treatment and surveillance
of hepatitis. A series of teleconferences took place in 2014,
in parallel with the organisation of the first HepHIV
Conference in Barcelona in October 2014, where the
first draft of the definition for late presentation was
presented and discussed [12]. Following the conference,
key stakeholders were consulted on the proposed consen-
sus definitions in a public hearing phase. The definitions
were finally endorsed by the EASL governing board in
September 2015.
Results
Two definitions relating to late presentation were agreed
upon (Table 1).
The term “late presentation for care” should be used
to refer to HBV or HCV-infected people who enter care
when substantial liver fibrosis is already present (i.e. they
present with advanced liver disease). This implies that
the time of HBV or HCV diagnosis is considered late, as
“late presenters” have not been diagnosed earlier. In con-
trast, the term “presentation with late stage liver disease”
should be reserved for the subgroup of these late pre-
senters who are additionally at greater imminent risk of
severe complications of liver disease or death. The term
“presentation for care” means attendance at a healthcare
facility that is able to monitor progression of chronic
hepatitis B and C and associated liver disease and initiate
appropriate medical care, including treatment.
Discussion
These consensus definitions may be considered for in-
clusion within countries’ routine viral hepatitis surveil-
lance systems. Investigations performed on the basis of a
common definition will enable epidemiological data to
be compared between countries and trends to be moni-
tored over time.
For this purpose the definition of “presentation with
advanced liver disease in patients with chronic hepatitis
B and C” includes several different technical procedures
to estimate the degree of liver fibrosis to improve its
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practicality, which all have different sensitivities and
specificities [13, 14]. In particular, the inclusion of APRI
and FIB-4 should enable this definition to be used on a
broad scale, and also in low-income countries. However,
since the accuracy of APRI in assessing fibrosis in HBV
infection has been challenged [15], APRI should only be
used in chronic hepatitis B in the absence of other tools
including FIB-4. Using a uniform cut-off for the recom-
mended tests for chronic hepatitis B and C may lead to
a loss in accuracy [15–17], but is in line with current
WHO recommendations [9, 10]. In addition, using the
same cut-offs for chronic hepatitis B and C increases the
practicality of this definition as a population-based tool.
The second definition of “presentation with late stage
liver disease in patients with chronic hepatitis B and C”
is based on clinical symptoms alone, with no need for
sophisticated technology. This enables its use in any
health care system. In some patients, particularly those
with chronic hepatitis B, hepatocellular carcinoma may
occur without cirrhosis, but usually after prolonged pe-
riods of chronic infection [18].
The two key indicators to be derived from using the
two definitions of late presentation of patients for
medical care with chronic hepatitis B and C within a
population of new referrals are: 1) the proportion of
referrals that fulfil either of these definitions, and 2) the
incidence of presenters with late stage liver disease in the
population.
If the definitions are implemented in surveillance
structures, the data on which these definitions are based
must be readily available from routine care in centres
that are specialised to diagnose and treat liver diseases.
To achieve this, these centres must adequately capture
data on liver fibrosis stage and presence of hepatocellu-
lar carcinoma or decompensated cirrhosis.
It is important that viral hepatitis surveillance systems
capture the public health consequences of these infec-
tions by focusing on the proportion of patients referred
to a specialised medical site who present late and/or
with advanced liver disease. In the past, this was demon-
strated by the introduction of a comparable definition of
late presentation with HIV. The broad acceptance of this
definition (defined as individuals newly presenting for
HIV care with a CD4 count below 350 cells/μl, or with
an AIDS-defining event) has allowed the percentages of
late presenters in various countries and regions to be
compared, and also allows changes in the numbers of
late presenters to be monitored after implementing im-
proved testing strategies [19, 20].
Using this definition has been particularly instrumental
in identifying risk factors for late presentation, and there-
fore has had an impact on new testing strategies. Indeed, a
recent Swiss cohort analysis showed that patients outside
established HIV risk groups are most likely to be late pre-
senters. Provider-initiated testing must therefore be im-
proved to reach these groups, which include heterosexual
men and women, and older patients [21].
The late presenter definition has also been used to
characterize a specific group of HIV patients with pro-
longed low CD4-positive cell counts, who behave very
differently to other HIV-infected patient groups. More
recently, a study on non-infectious comorbidities re-
vealed that these were also far more prevalent in late
presenters [22]. In summary, the definition of late pres-
entation has been instrumental in better understanding
clinical presentation, course and epidemiology of HIV in
various regions of the world.
The two definitions presented here for liver disease in
patients with chronic hepatitis B and C can be used for
different purposes. Firstly, they will unify methods of
monitoring and evaluating the effectiveness of testing
and referral services. For example, if a large percentage
of patients are “late presenters”, it implies that interven-
tion testing needs improvement to ensure earlier diagno-
sis. As such, the definitions can be used to monitor the
effect of interventions that aim to reduce the number of
late presenters. Secondly, their use will enable future
studies across Europe to determine the size of the popu-
lation at risk, and to identify vulnerable groups and risk
factors for late presentation. They will also increase
Table 1 Consensus definition of late presentation with chronic
viral hepatitis for medical care
Definition Description
Presentation with advanced liver
disease in untreated patients with
chronic hepatitis B and C
A patient with chronic hepatitis B
or C and significant fibrosis assessed
by one of the following: serologic
fibrosis score≥ F3 (assessed by APRI
score > 1.5, FIB-4 > 3.25, Fibrotest >
0.59 or alternatively a transient
elastography (FibroScan) > 9.5 kPa)
or liver biopsy (≥ METAVIR stage F3)
in patients with no previous antiviral
treatmenta.
Presentation with late stage liver
disease in untreated patients with
chronic hepatitis B and C
Presence of at least one symptom
of decompensated cirrhosis
(jaundice, hepatic encephalopathy,
clinically detectable ascites, variceal
bleeding) and/or hepatocellular
carcinoma in patients with no
previous antiviral treatmentb.
aGeneral comments: advanced liver disease in patients with chronic hepatitis B
and C is a definition for capturing all cirrhotics and patients with pre-cirrhosis.
On the basis of regular testing of the aspartate transaminase level (AST), alanine
transaminase level (ALT), gamma glutamyl transferase level (GGT), cholesterol and
platelet count, it is possible to calculate the aspartate transaminase to platelets
radio index (APRI) as: APRI = (AST/upper limit of normal [ULN])/platelet (109/L) x
100), or to calculate the FIB-4 as FIB-4 = (age x AST) / (platelets x (sqr (ALT) or with
more extensive laboratory assessments the commercially available Fibrotest. APRI
and FIB-4 may have lower sensitivity and specifity in calculating advanced fibrosis
and cirrhosis patients with chronic hepatitis B compared to chronic hepatitis C.
The APRI score may not be reliable if a patient suffers from another condition
that affects the platelet count (e.g. HIV infection, immune thrombopenia etc), and
therefore transient elastography (e.g. FibroScan) is preferred.
bIn the absence of other explanatory factors/aetiologies aside HBV, HCV or HDV
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understanding of the social and medical barriers that
limit access to healthcare in different European coun-
tries, and may initiate studies on access to treatment for
late presenters across the region. It would therefore be
beneficial if all national health agencies, institutions and
researchers could implement these consensus definitions
when reporting surveillance or research data on late
presentation of chronic hepatitis B or C.
These consensus definitions of late presentation for
viral hepatitis provide a useful tool for public health au-
thorities in Europe and elsewhere, to gain a better un-
derstanding of epidemics. They will help to improve the
quality of available epidemiological information on viral
hepatitis and the prevention and control responses to
the viral hepatitis epidemic.
Endnotes
1Case definitions for hepatitis B and C vary across
European countries. Countries in the European Union
(EU) and European Economic Area (EEA) are requested
to follow EU 2012 case definitions for reporting at the
European level. 2012/506/EC – Commission Implement-
ing Decision of 8 August 2012 amending Decision 2002/
253/EC laying down case definitions for reporting com-
municable diseases to the Community network under
Decision No 2119/98/EC of the European Parliament
and of the Council.
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